Linked Life Data

20398764

Source:http://linkedlifedata.com/resource/pubmed/id/20398764

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2010-7-19
pubmed:abstractText
Eldecalcitol is a vitamin D3 analog under clinical development for the treatment of osteoporosis. Previous studies have shown that the binding activities of eldecalcitol to the serum vitamin D binding protein (DBP) and the vitamin D receptor (VDR) are 421.9% and 44.6% of those of calcitriol, respectively, and also, suppressed parathyroid hormone (PTH) production by only 3.5% of calcitriol in vitro using bovine parathyroid cell primary culture. Here, we compared in vivo activities of eldecalcitol on serum calcium, BMD and PTH with those of calcitriol. Six-week old male rats were given either vehicle (medium chain triglyceride; n=6), eldecalcitol (0.025, 0.05, 0.1, 0.25, 0.5 microg/kg; n=6) or calcitriol (0.25, 0.5, 1.0, 2.5, 5 microg/kg; n=6) daily for 14 days by oral gavages. Eldecalcitol was approximately five-times more potent than calcitriol in increasing serum calcium. Eldecalcitol significantly increased lumbar spine BMD, however, calcitriol had no effect on BMD at any given doses. On the contrary, eldecalcitol did not affect PTH mRNA synthesis at the normocalcemic doses, despite the BMD was higher than normal. These observations indicate that, as previous in vitro study suggested, eldecalcitol is less effective in suppressing PTH compared to calcitriol.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1879-1220
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
121
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
281-3
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Eldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivo.
pubmed:affiliation
Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
pubmed:publicationType
Journal Article